Cargando…

Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience

BACKGROUND: One of the most valued targets in inflammatory bowel disease (IBD) is for physicians to provide and patients to receive a high‐level quality of care. This study aimed to evaluate the implementation of a nationwide quality certification programme for IBD units. METHODS: Identification of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barreiro‐de Acosta, Manuel, Gutiérrez, Ana, Zabana, Yamile, Beltrán, Belén, Calvet, Xavier, Chaparro, María, Domènech, Eugeni, Esteve, Maria, Panés, Julian, Gisbert, Javier P., Nos, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435246/ https://www.ncbi.nlm.nih.gov/pubmed/34089303 http://dx.doi.org/10.1002/ueg2.12105

Ejemplares similares

Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach
por: Pérez-Brocal, Vicente, et al.
Publicado: (2013)

Editorial: Postoperative management of Crohn's disease: One size does not fit all
por: Domènech, Eugeni, et al.
Publicado: (2023)

Mild to moderate ulcerative colitis: Call me by my name
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Surfing the web as a patient with IBD: New horizons
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2023)

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
por: D'Amico, Ferdinando, et al.
Publicado: (2021)

Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
por: Chaparro, María, et al.
Publicado: (2019)

Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003–2013
por: Ahmad, Ahmir, et al.
Publicado: (2018)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

Clinical procedures used to diagnose inflammatory bowel disease: real-world evidence from a Danish nationwide population-based study
por: Rasmussen, Nathalie Fogh, et al.
Publicado: (2022)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis
por: Dotti, Isabella, et al.
Publicado: (2017)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme
por: Miehlke, Stephan, et al.
Publicado: (2022)

Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome
por: Ruiz, Pedro A, et al.
Publicado: (2017)

Impact of a physician-led exercise programme on quality of life, muscle mass and clinical response in inflammatory bowel disease patients during induction with disease-modifying therapy: a study protocol
por: Mc Gettigan, Neasa, et al.
Publicado: (2022)

Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
por: Magro, Fernando, et al.
Publicado: (2023)

Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature
por: Caio, Giacomo, et al.
Publicado: (2021)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature
por: Scioli, Maria Giovanna, et al.
Publicado: (2014)

Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey
por: Cheema, Madiha, et al.
Publicado: (2021)

Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
por: Riestra, Sabino, et al.
Publicado: (2022)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis
por: Tursi, Antonio, et al.
Publicado: (2023)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2023)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Long‐term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
por: Festa, Stefano, et al.
Publicado: (2021)

BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023)

Faster and less invasive tools to identify patients with ileal colonization by adherent‐invasive E. coli in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance
por: Aschenbrenner, Dominik, et al.
Publicado: (2021)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Developing in vitro expanded CD45RA(+) regulatory T cells as an adoptive cell therapy for Crohn's disease
por: Canavan, James B, et al.
Publicado: (2016)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d3qdcro3cvhuk6gg7mnv6o8co1